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SHORT REPORT
Aberrant p15 gene promoter methylation in therapy-related
myelodysplastic syndrome and acute myeloid leukaemia:
clinicopathological and karyotypic associations
W. Y. Au,1 A. Fung,1 C. Man,1 S. K. Ma,2 T. S. Wan,2 R. Liang1 and Y. L. Kwong1 1University Department
of Medicine, and 2University Department of Pathology, Queen Mary Hospital, Hong Kong
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Summary. Seventeen patients with therapy-related myel-
odysplastic syndrome/acute myeloid leukaemia (t-MDS/
AML) were examined for aberrant p15 gene methylation
by methylation-specific polymerase chain reaction. Ten
patients (58%) showed p15 methylation, which was signi-
ficantly related to monosomy/deletion of chromosome 7q,
but not to antecedent chemotherapy, blast count, leukaemic
evolution or survival. In three of six patients with marrow
samples obtained prior to the diagnosis of t-MDS/AML, p15
methylation predated disease development by up to 2 years.
Bone marrow transplantation led to the disappearance of
p15 methylation in one patient. These results showed that
p15 methylation was an early event in the evolution of
some t-MDS/AML patients.
Keywords: therapy-related acute myeloid leukaemia/
myelodysplasia, p15 methylation.
Therapy-related myelodysplasia and acute myeloid leukae-
mia (t-MDS/AML) are distinct disorders in the World Health
Organization (WHO) classification of myeloid malignancies.
Alkylating agent-related t-MDS/AML has a longer latency,
and is associated with monosomies/deletions of chromo-
somes 5 and 7. Topoisomerase II inhibitor-related t-MDS/
AML has a shorter latency and is associated with MLL gene
rearrangements. Both types are characterized by multilin-
eage dysplasia, a preleukaemic phase and a poor prognosis.
In addition, t-AML cases with well-defined cytogenetic
abnormalities, including t(15;17)(q22;q21), t(8;21)
(q22;q22) and inv(16)(p13q22), also occur (Rowley &
Olney, 2002). They are, however, comparable clinicopatho-
logically and prognostically to de novo AML with similar
cytogenetic abnormalities.
Aberrant promoter CpG methylation, leading to tran-
scriptional silencing, is increasingly recognized as an
important pathogenetic event in AML. The p15 gene,
critically involved in cell cycle regulation, is commonly
methylated in de novo AML, occurring in up to 93% of
patients (Chim et al, 2001).
In this study, we investigated a consecutive series of
t-MDS/AML to define the frequency and time course of
aberrant p15 methylation in this disorder.
MATERIALS AND METHODS
Patients. t-MDS/AML were diagnosed according to WHO
classification criteria. Cytogenetic analyses were performed
on overnight unstimulated cultures of marrow cells. Meta-
phases were Giemsa banded and karyotyped according to
the International System for Human Cytogenetic Nomen-
clature.
Methylation-specific polymerase chain reaction (MSP) for
aberrant p15 methylation. MSP for aberrant p15 methyla-
tion was performed on marrow DNA as described (Chim
et al, 2001). Briefly, 1 lg of genomic DNA was modified
with bisulphite (CpGenome DNA modification kit; Intergen,
USA), purified and subjected to MSP that detected the
methylated (M) and unmethylated (U) promoter sequences.
Positive and negative controls included universally methy-
lated DNA (Intergen) and normal donor DNA respectively.
The sensitivity of the method was estimated to be
10)3)10)4 (Chim et al, 2001).
RESULTS
Patients, clinicopathological features and treatment outcome
Seventeen consecutive patients were studied (Table I), five
of whom have been reported briefly (Kwong et al, 1998;
Au et al, 2000, 2001a,b). Antecedent chemotherapy
included single agents (azathioprine/cyclophosphamide),
combination chemotherapy and conditioning regimens for
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bone marrow transplantation (BMT). Only one patient had
received radiotherapy. The median latency to t-MDS/AML
was 7 years (range 3–13 years). The diagnoses included
t-AML (n ¼ 5), acute promyelocytic leukaemia (APL,
n ¼ 2), refractory anaemia with excess blasts-1 (RAEB-1,
n ¼ 3), RAEB-2 (n ¼ 3), chronic myelomonocytic leukae-
mia-2 (CMML-2, n ¼ 1) and refractory cytopenia with
multilineage dysplasia (RCMD, n ¼ 3). Cytogenetic analysis
showed normal karyotypes in two patients, t(15;17) in two
patients with APL, monosomies/deletions involving chro-
mosomes 5q and/or 7q ()5/5q–, )7/7q–) and other
complex changes in 11 patients, and trisomies involving
chromosomes 8, 9 and 21 in two patients. The median
survival was 8 months (1–44 months) with or without
treatment. Three patients were in complete remission after
receiving allogeneic BMT (two patients with t-MDS) and
treatment with arsenic trioxide (one patient with APL). One
patient with RCMD was alive with disease.
Aberrant p15 gene methylation
Aberrant p15 methylation was detected in 10 patients
(59%) at the diagnosis of t-MDS/AML. Antecedent chemo-
therapy and diagnosis (t-MDS or t-AML) were unrelated
to the occurrence of p15 gene methylation. Cytogenetically,
the p15-unmethylated group contained all the patients with
normal karyoytpes (n ¼ 2), t(15;17) (n ¼ 2), and )5/5q–
in the absence of )7/7q– (n ¼ 3). However, p15 methyla-
tion was significantly associated with )7/7q– (P ¼ 0Æ002).
p15 methylation had no influence on the median blast
percentage and survival (Table I).
Serial analysis of p15 methylation
Only six patients had marrow samples available for testing
before and/or after the diagnosis of t-MDS/AML. In three
patients (patients 3, 7 and 15), aberrant p15 methylation
was first detected at 26, 4 and 17 months before the
diagnosis of t-MDS (7, 5Æ5 and 2Æ5 years after chemother-
apy) respectively. In patient 3, p15 methylation was
undetectable in the marrow after BMT (Fig 1).
DISCUSSION
t-MDS/AML is an important long-term complication
after chemotherapy/radiotherapy (Pedersen-Bjergaard et al,
2000). Apart from karyotypic aberrations, other genetic
alterations, particularly aberrant methylation leading to
gene silencing, are not well defined in t-MDS/AML.
Furthermore, the similarities/differences in genetic altera-
tions in t-MDS/AML and de novo MDS/AML with similar
cytogenetic changes are also largely unknown.
Our results showed that p15 methylation occurred
frequently in t-MDS/AML. In the comparison of t-MDS/
AML with de novo MDS/AML, there were a number of
interesting observations. p15 methylation was significantly
associated with )7/7q– in t-MDS/AML. Previous studies
have shown that t-MDS/AML with )7/7q– generally has
fewer additional cytogenetic aberrations and is often asso-
ciated with mutations of the RAS gene (Pedersen-Bjergaard
et al, 2002). Our observations suggest that p15 methylation
might be another step, in addition to )7/7q–, during the
pathogenesis of t-MDS/AML. However, our findings were
observed in a relatively small number of patients and will
need to be validated in studies of larger numbers of patients
with both de novo as well as t-MDS/AML.
Although the frequency of p15 methylation in t-MDS/
AML in this study was similar to de novo MDS (34–50%)
(Uchida et al, 1997; Tien et al, 2001) and AML (54–93%)
(Wong et al, 2000; Chim et al, 2001), pattern differences
were observed. In the present study, p15 methylation
was absent in both patients with t-APL, which contrasted
with the high frequency of p15 methylation (73–100%)
reported in de novo APL (Wong et al, 2000; Chim et al,
2001). Furthermore, blast percentage and evolution from
MDS to AML were unrelated to p15 methylation in
t-MDS/AML, which was different from de novo MDS
(Quesnel et al, 1998), where an increase in blasts and
leukaemic evolution were associated with p15 methyla-
tion. The reasons for these differences are not clear and
A
B
C
Fig 1. MSP for p15 methylation. Primers were for M sequence
respectively: forward MF: 5¢-TGA GGA TTT CGC GAC GCG TTC-3¢,
reverse MR: 5¢-CGT ACA ATA ACC GAA CGA CCG ATC G-3¢; for U
sequence: forward UF: 5¢-TGA GGA TTT TGT GAT GTG TTT-3¢,
reverse UR: 5¢-CAT ACA ATA ACC AAA CAA CCA ATC A-3¢. PCR
products for both the M and U sequences were 151 bp in size. B:
reagent blank; N: normal donor DNA; P: positive control with
universally methylated DNA. (A) In patient 3, p15 methylation was
first detected (weakly) at 26 months ()26 m) before t-MDS/AML
was diagnosed. It disappeared after stem cell transplantation
(SCT+). (B) In patient 15, p15 methylation was first detected at
4 months ()4 m) before t-MDS/AML was diagnosed. In patient 7,
p15 methylation was detected at 17 months ()17 m) before t-MDS/
AML was diagnosed, but not at 37 months ()37 m). (C) Patients 6,
11 and 13 were negative for p15 methylation, whereas patients 4
and 10 were positive.
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will need to be further investigated in larger numbers of
patients.
Finally, aberrant p15 methylation might precede t-MDS/
AML by several years, implying that this was an early event
during disease evolution. Similar observations have not
been made in de novo MDS/AML, as antecedent marrow
samples are rarely available. With the high sensitivity of
MSP (10)3)10)4), these observations suggested that exam-
ination for p15 methylation might be useful in detecting the
early emergence of t-MDS/AML clones in selected high-risk
patients. Further prospective studies will be required to
verify whether earlier detection of t-MDS/AML may impact
on treatment results and prognosis in these patients.
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